{
  "source": "PA-Notification-Tryngolza.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1470-1\nProgram Prior Authorization/Notification\nMedication Tryngolza™ (olezarsen)\nP&T Approval Date 2/2025\nEffective Date 5/1/2025\n1. Background:\nTryngolza™ (olezarsen) is an APOC-III-directed antisense oligonucleotide (ASO) indicated as\nan adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome\n(FCS).\n2. Coverage Criteriaa:\nA. Initial Authorization\n1. Tryngolza will be approved based on the following criterion:\na. Diagnosis of familial chylomicronemia syndrome (FCS) (i.e., monogenic\nchylomicronemia, type 1 hyperlipoproteinemia)\nAuthorization will be issued for 12 months\nB. Reauthorization\n1. Tryngolza will be approved based on the following criterion:\na. Documentation of positive clinical response to Tryngolza therapy (e.g., reduction in\ntriglycerides, reduction in episodes of acute pancreatitis)\nAuthorization will be issued for 12 months\na State mandates may apply. Any federal regulatory requirements and the member specific benefit\nplan coverage may also impact coverage criteria. Other policies and utilization management\nprograms may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n• Supply limits and medical necessity may be in place.\n4. References:\n1. Tryngolza [package insert]. Carlsbad, CA: Ionis Pharmaceuticals, Inc.; December 2024.\n© 2025 UnitedHealthcare Services, Inc.\n1\nProgram Prior Authorization/Notification - Tryngolza™ (olezarsen)\nChange Control\nDate Change\n2/2025 New program.\n© 2025 UnitedHealthcare Services, Inc.\n2"
  ]
}